Age-related diseases cost $1T+ annually in global healthcare
annual global healthcare costs
Alzheimer's • Cancer • CVD • Diabetes • Renal Failure
Leading cause of death globally, costs projected to triple from current levels. [1]
Approaching $1T annually worldwide in direct health expenditure.
Now the leading condition driving insurer medical costs globally. [2]
Nearly all US healthcare spending goes to chronic and mental health conditions. [3]
Years living with chronic disease, disability, or frailty [1]
Fewer workers per retiree, escalating fiscal pressure on healthcare systems
Already over 55 million Americans aged 65 or older today. [1]
Projected 65+ population will reach almost 80 million. [2]
1 in 5 Americans will be 65+ by 2030. [2]
Per-person spending for 65+ is 5× higher than for children. [2]
Without interventions that alter the trajectory of age-related disease, cost curves remain exponential
Average healthcare cost during retirement, more than doubled since 2002. [1]
Expected healthcare cost growth for US employers in 2025. [2]
Per-capita spending for 65+ compared to working-age adults. [3]
Solutions that extend healthspan, reduce costs, and improve lives
If 90% of spend is tied to chronic conditions linked to aging, even single-digit percentage reductions cascade into hundreds of billions in savings.
Why Now
A demographic shift creating a multi-trillion dollar opportunity
people over 60 by 2050
United Nations
The UN describes global aging as "a defining trend of our time" and a "major success story"
The UN projects the global population aged 60+ will roughly double by 2050. [1]
Population aged 65+ expected to reach around 1.6 billion. [2]
The "oldest old" (80+) will more than triple to 447M by 2050. [2]
In Asia, one in four people will be over 60 by 2050. [3]
Validated genomic tools, mechanism-based geroscience, and AI-native R&D have transformed longevity into an investable category
Evolved from basic gene editing to base editing, prime editing, and epigenome editing—enabling precise interventions in age-related pathways.
Drugs that selectively clear senescent "zombie" cells, implicated in chronic inflammation and age-related diseases.
Applied to multi-omics datasets and biomarker streams to identify aging signatures and enable biological-age-driven interventions.
A multi-trillion dollar market underpinned by demographic certainty
Seniors will account for one-quarter of global consumption by 2050. [1]
Healthcare, financial products, housing, caregiving, and consumer markets. [1]
Global life expectancy projected to reach 77 years by 2050. [1]
Capture the $7T+ Longevity Economy
Demographic inevitability meets scientific readiness
Returns
Two proven paths to liquidity for longevity investments
Biotech IPOs remain a core liquidity event, especially for companies with differentiated clinical data in age-related disease.
The post-2021 correction led to a disciplined IPO market focused on clinical-stage, de-risked assets. [1]
By 2023, all US biotech IPOs had clinical-stage assets, with roughly one-third at Phase III. [1]
Longevity-focused biotechs raised over $2 billion via IPOs in 2023 alone. [2]
Investors reward platforms that pair bold aging biology with credible, near-term milestones. [3]
Large pharma companies facing patent cliffs are increasingly acquiring longevity-adjacent assets to sustain growth.
Global anti-aging therapeutics projected to grow from $5.7B (2024) to $34.6B by 2035. [1]
Institutional investors expect continued M&A as pharma uses acquisitions to access innovative platforms. [2]
Longevity mechanisms intersect with existing pharma markets—cardiometabolic, oncology, ophthalmology. [3]
Longevity VC funds raised over $3B in 2023, seeding future acquisition targets. [4]
Global anti-aging therapeutics market projection [1]
Pharma–Senolytics Acquisition Model
Based on recent longevity M&A activity [1]
The Opportunity
Credible age-related disease indications are sufficient for pharma-scale exits
Target validated aging pathways with clear clinical endpoints
Biomarker-driven approaches enable faster proof-of-concept
Pharma acquirers value platform technologies across multiple indications